We are live on ! Find out more
NKTR icon

Nektar Therapeutics
NKTR

138 hedge funds and large institutions have $183M invested in Nektar Therapeutics in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 37 increasing their positions, 34 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

691% more call options, than puts

Call options by funds: $182K | Put options by funds: $23K

29% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 17

9% more capital invested

Capital invested by funds: $168M → $183M (+$15M)

4% more funds holding

Funds holding: 133 → 138 (+5)

9% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 34

0.19% more ownership

Funds ownership: 4.91% → 5.1% (+0.19%)

Holders
138
Holders Change
+5
Holders Change %
+3.76%
% of All Funds
1.98%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
37
Reduced
34
Closed
17
Calls
$182K
Puts
$23K
Net Calls
+$159K
Net Calls Change
+$186K

Top Buyers

1
EAM
Eventide Asset Management
Massachusetts
+$2.38M
2
BCM
Bridgeway Capital Management
Texas
+$1.73M
3
WP
Woodline Partners
California
+$1.41M
4
Northern Trust
Northern Trust
Illinois
+$1.21M
5
BlackRock
BlackRock
New York
+$1.03M

Top Sellers

1
DTC
Deep Track Capital
Connecticut
-$2.48M
2
Morgan Stanley
Morgan Stanley
New York
-$923K
3
GCP
GSA Capital Partners
United Kingdom
-$911K
4
Two Sigma Investments
Two Sigma Investments
New York
-$567K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$426K
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
51
T. Rowe Price Associates
Maryland
$237K – – –
Ohio Public Employees Retirement System (OPERS)
52
Ohio Public Employees Retirement System (OPERS)
Ohio
$207K -$1.28K -67 -0.6%
MAM
53
Marquette Asset Management
Minnesota
$206K – – –
Cambridge Investment Research Advisors
54
Cambridge Investment Research Advisors
Iowa
$172K +$11.8K +620 +8%
Citigroup
55
Citigroup
New York
$169K +$114K +5,998 +224%
UBS Group
56
UBS Group
Switzerland
$146K +$69.9K +3,667 +96%
MIM
57
MetLife Investment Management
New Jersey
$138K +$76.2K +4,000 +129%
HSBC Holdings
58
HSBC Holdings
United Kingdom
$129K +$28.7K +1,508 +30%
Mirae Asset Global ETFs Holdings
59
Mirae Asset Global ETFs Holdings
Hong Kong
$127K +$124K +6,530 New
CF
60
Corebridge Financial
Texas
$124K -$743 -39 -0.6%
SG Americas Securities
61
SG Americas Securities
New York
$124K +$28.3K +1,486 +30%
Jane Street
62
Jane Street
New York
$119K +$38.7K +2,032 +50%
Russell Investments Group
63
Russell Investments Group
United Kingdom
$116K -$324 -17 -0.3%
Deutsche Bank
64
Deutsche Bank
Germany
$115K +$113K +5,903 New
Wells Fargo
65
Wells Fargo
California
$112K +$4.67K +245 +4%
CS
66
Candriam SCA
Luxembourg
$103K – – –
ACM
67
ADAR1 Capital Management
Texas
$88.1K +$86.1K +4,517 New
Manulife (Manufacturers Life Insurance)
68
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$86.1K +$84.2K +4,415 New
LPL Financial
69
LPL Financial
California
$85.5K +$20.9K +1,097 +33%
SEI Investments
70
SEI Investments
Pennsylvania
$81.2K +$79.4K +4,167 New
VOYA Investment Management
71
VOYA Investment Management
Georgia
$78.6K -$1.85K -97 -2%
Tudor Investment Corp
72
Tudor Investment Corp
Connecticut
$74.2K – – –
Prudential Financial
73
Prudential Financial
New Jersey
$73.1K – – –
Mackenzie Financial
74
Mackenzie Financial
Ontario, Canada
$67.8K +$10.6K +557 +19%
AP
75
Adero Partners
California
$67K – – –
1 2
3
4 5

NKTR Hedge Fund Activity: Q3 2024 in Review

138 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q3 2024, worth a combined $183M — up 8.9% from $168M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new NKTR positions and 17 closed out — a net gain of 5 holders — while 37 added to existing stakes and 34 trimmed.

The largest buyer was Eventide Asset Management, adding an estimated $2.38M. The largest seller was Deep Track Capital, cutting an estimated $2.48M.

  • 138 institutional investors held Nektar Therapeutics (NKTR) as of Q3 2024, up from 133 in Q2 2024.
  • Funds reported $183M of Nektar Therapeutics stock for Q3 2024, up 8.9% quarter-over-quarter.
  • 22 funds opened new Nektar Therapeutics positions in Q3 2024 and 17 closed out, a net change of +5 holders.
  • The largest Nektar Therapeutics buyer in Q3 2024 was Eventide Asset Management, an estimated $2.38M added.
  • The largest Nektar Therapeutics seller in Q3 2024 was Deep Track Capital, an estimated $2.48M sold.

Based on aggregated 13F filings for Q3 2024.